Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Voyager TherapeuticsFRA:VT6 +3.75%43 3-Year EPS without NRI Growth Rate is -19.00% as of Jun. 2026. GuruFocus rates FRA:VT6 with a GF Score™ of 43/100 and a GF Value™ of €1.12 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,160 Biotechnology companies, Voyager Therapeutics ranks worse than 85.17% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was -19.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Voyager Therapeutics was 44.70% per year. The lowest was -33.50% per year. And the median was 10.25% per year.
Voyager Therapeutics (FRA:VT6) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Voyager Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
FRA:VT6 vs CHRS, KROS, DTIL: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Voyager Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Voyager Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -19.00% mean?
Voyager Therapeutics (FRA:VT6) has a 3-Year EPS without NRI Growth Rate of -19.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Voyager Therapeutics and its competitors. According to the industry distribution chart, Voyager Therapeutics ranks #988 out of 1160 companies in the Biotechnology industry, placing it in the top 85.2%.
Is Voyager Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Voyager Therapeutics' current 3-Year EPS without NRI Growth Rate is -19.00%. Based on the distribution chart, Voyager Therapeutics ranks #988 out of 1160 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Voyager Therapeutics has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' 3-Year EPS without NRI Growth Rate compare to CHRS and KROS?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #988 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Voyager Therapeutics in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Voyager Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyager Therapeutics's current 3-Year EPS without NRI Growth Rate is -19.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.12, compared to a current price of €2.87 — trading 156.6% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -19.00%. Voyager Therapeutics' overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current 3-Year EPS without NRI Growth Rate is -19.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of €2.87 is trading 156.6% above its estimated GF Value™ of €1.12.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:VT6:
3-Year EPS without NRI Growth Rate: -19.00%
GF Value™: €1.12 vs. price of €2.87 (156.6% above fair value)
No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
43GF Score
Get the complete analysis for FRA:VT6
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VT6 has been successfully added to your 
